Australia's TGA approves Feraccru

Shield Therapeutics plc

("Shield Therapeutics" or the "Company")

Australia's Therapeutic Goods Administration (TGA) approves Feraccru® to treat Iron Deficiency
with or without anaemia in adults

London, UK, 9 March 2021: Shield Therapeutics plc (LSE: STX), a commercial stage pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru®/Accrufer® (ferric maltol), notes that Australia's Therapeutics Goods Administration has registered Feraccru® in the Australian Register of Therapeutic Goods to treat iron deficiency with or without anaemia in adults.

Feraccru® is already approved in the UK, European Union, Switzerland and United States for the treatment of iron deficiency with or without anaemia in adults. Norgine Pty Ltd will lead all marketing activities in Australia. 

The Therapeutic Goods Administration (TGA) is Australia's regulatory authority for medicinal products ("therapeutic goods").

For further information, please contact:

About Shield

Shield is a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with its lead product Feraccru ® /Accrufer ® (ferric maltol) ®, a novel, stable, non-salt based oral therapy for adults with iron deficiency with or without anaemia. Shield is quoted on AIM (STX). For more information about Shield, please see www.shieldtherapeutics.com